Novartis AG
PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE
Last updated:
Abstract:
PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
Status:
Application
Type:
Utility
Filling date:
28 Oct 2019
Issue date:
20 Aug 2020